-
Takeda's Narcolepsy Candidate Gets FDA Breakthrough Therapy Tag
Wednesday, July 28, 2021 - 11:22am | 179Read More...The FDA has granted Breakthrough Therapy Designation to Takeda Pharmaceutical Company Limited's (NYSE: TAK) TAK-994 for excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1). The oral orexin agonist is currently in Phase 2 study. EDS is a...
-
Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock
Monday, May 24, 2021 - 12:03pm | 251Read More...The FDA has granted Breakthrough Therapy designation to Verastem Inc (NASDAQ: VSTM) for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy...
-
Acadia Continues Huge Rise Following FDA Panel Vote
Wednesday, March 30, 2016 - 7:52am | 177Read More...Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) were trading higher by more than 22 percent early Wednesday morning. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease,...
